The earnings call provided a mix of optimistic future prospects and current financial challenges. While there are significant potential opportunities, such as large cash recovery and new ventures, there are also current concerns regarding stock performance and financial stability.

Company Guidance

During the ProPhase Labs Second Quarter 2025 Results call, CEO Ted Karkus provided guidance on several key initiatives and metrics. He highlighted the company's ongoing efforts to recover $50 million from COVID-19 receivables through Crown Medical collections, an amount that is more than triple the company's current market cap of around $0.35 per share. Karkus expressed confidence in the anticipated recovery, noting that Crown Medical's analysis suggests a net amount of approximately $73 million, with ProPhase retaining about $50 million after contingency fees. Additionally, Karkus discussed the BE-Smart esophageal cancer test, emphasizing its potential to significantly impact the market by offering a more accurate diagnostic test for esophageal cancer, a disease with a high mortality rate. He also mentioned the restructuring of Nebula Genomics, which now operates with reduced overhead, and the potential for future growth or sale. Karkus concluded by discussing the upcoming proxy vote to increase authorized shares to 1 billion, aiming to attract large partners for a potential crypto treasury strategy, drawing parallels to the company's previous success in pivoting to COVID testing.

Potential $50 Million Recovery from COVID-19 Receivables

ProPhase Labs is targeting over $50 million in net near-term cash recovery from COVID-19 receivables through a legal strategy involving Crown Medical collections and 1,100 insurance companies.

Advancement in Esophageal Cancer Test

ProPhase Labs has been awarded a critical patent for its BE-Smart esophageal cancer test, which has the potential to diagnose esophageal cancer earlier and more accurately, potentially saving lives and reducing healthcare costs.

Restructuring of Nebula Genomics

Nebula Genomics has been restructured to reduce costs significantly, and the company is exploring strategic alternatives which may include a potential sale.

Crypto Treasury Strategy Initiative

ProPhase Labs is exploring entering the crypto treasury strategy with potential significant partners, which could provide substantial financial growth opportunities.

Prophase Labs (PRPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PRPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	- / -	-0.35	―	―	―
Aug 13, 2025	2025 (Q2)	-0.15 / -0.11	-0.33	66.67% (+0.22)	―
May 20, 2025	2025 (Q1)	- / -0.13	-0.07	-85.71% (-0.06)	―
Mar 31, 2025	2024 (Q4)	-0.18 / -0.13	-0.07	-85.71% (-0.06)	―
Nov 13, 2024	2024 (Q3)	-0.31 / -0.35	-0.3	-16.67% (-0.05)	―
Aug 14, 2024	2024 (Q2)	-0.08 / -0.33	-0.2	-65.00% (-0.13)	―
May 09, 2024	2024 (Q1)	-0.28 / -0.07	0.03	-333.33% (-0.10)	―
Mar 15, 2024	2023 (Q4)	-0.26 / -0.51	-0.15	-240.00% (-0.36)	―
Nov 09, 2023	2023 (Q3)	-0.20 / -0.30	0.06	-600.00% (-0.36)	―
Aug 10, 2023	2023 (Q2)	-0.14 / -0.20	0.4	-150.00% (-0.60)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PRPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.35	$0.33	-5.71%
May 20, 2025	$0.32	$0.33	+3.13%
Mar 31, 2025	$0.44	$0.40	-9.09%
Nov 13, 2024	$0.74	$0.77	+4.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Prophase Labs (PRPH) report earnings?

Prophase Labs (PRPH) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Prophase Labs (PRPH) earnings time?

Prophase Labs (PRPH) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PRPH EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing